Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CEST
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at [email protected]

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
06/01 Immunomedics to Present at Jefferies 2017 Global Healthcare Conference
05/10 IMMUNOMEDICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
05/10 IMMUNOMEDICS, INC. (NASDAQ : IMMU) Files An 8-K Results of Operations and Financ..
05/10 IMMUNOMEDICS : reports 3Q loss
05/10 IMMUNOMEDICS INC : Results of Operations and Financial Condition, Financial Stat..
05/10 Immunomedics Announces Third Quarter Fiscal 2017 Results and Clinical Program..
05/10 Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2..
05/09 IMMUNOMEDICS : SPECT/CT Combined with Fluorescence Imaging Detects Micrometastas..
05/08 MONDAY BIOTECH MOVERS : Immunomedics, Inc. (NASDAQ:IMMU), Puma Biotechnology Inc..
05/08 IMMUNOMEDICS, INC. : Today's Research Report on Biotech Stocks to Watch: Immunom..
More news
Sector news : Biotechnology & Medical Research - NEC
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
06/27 DOVA PHARMACEUTICALS : A Different Business Model Could Lead To Success
06/09 Immunomedics (IMMU) Presents At Jefferies 2017 Global Healthcare Conference -..
06/08 Seattle Tries To Move Adcetris Into The Upper Echelon
05/26 Premarket analyst action - healthcare
05/16 After Hours Gainers / Losers
Advertisement
Financials ($)
Sales 2017 4,77 M
EBIT 2017 -63,0 M
Net income 2017 -121 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 198x
Capi. / Sales 2018 50,0x
Capitalization 944 M
More Financials
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Full-screen chart
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 11,8 $
Spread / Average Target 38%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Cynthia L. Sullivan President, Chief Executive Officer & Director
David M. Goldenberg Chairman, Chief Scientific & Patent Officer
Michael R. Garone Chief Financial Officer & Vice President-Finance
William A. Wegener Chief Medical Officer
Brian A. Markison Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.133.24%944
INCYTE CORPORATION29.96%26 684
QUINTILES IMS HOLDINGS..17.65%19 309
LONZA GROUP27.49%16 098
CELLTRION, INC.--.--%12 362
ALKERMES PLC4.89%8 750
More Results